Diseases and their cost is very high. “Biotechnological products are few units at a very high price and are urgently us for diseases where the patient risks his life,” says Sigman. A biosimilar in a clone of a biological drug. Their cost is considerably lower and their market is promising: today they represent % of the world drug market, more than , million dollars, and it is expect that they will reach % in the next ten years, especially due to the expiration of patents. In Sigman creat mAbxience, a division of Chemo specializing in monoclonal antibodies, or mAbs, biosimilars us to neutralize foreign objects such as tumors. In he inaugurat the pilot plant in Munro, an old semi-abandon industrial hub in the north of the province of Buenos Aires.
Of Belonging Being More Benevolent
The company soon made agreements with laboratories in Russia, Iran, Turkey, and Southeast Asia. Sigman’s biotechnological adventures in America know two milestones. The first is the Togo Email List development of a vaccine to treat lung cancer. A project that Sigman began in the mid- s in Cuba, with the development of the NgcCM antigen, and culminat in with the presentation of Racotumomab , the first vaccine that makes lung cancer chronic, transforming a deadly disease into a treatable disease such as diabetes or hypertension. The years of research and development involv Sigman’s companies, national universities, Cuban and Argentine research centers (including the National Council for Scientific and Technical Research of Argentina) and the support of two ministries.
With The Latter Thus The Three Elites
The second milestone was the creation of Sinergium Biotech. During the H N flu pandemic, Sigman propos to the Argentine government, through the then Minister of Health Juan Manzur, a pharmaceutical Aero Leads technology transfer project in exchange for the granting of a provisional monopoly, inspir by a similar project of the Brazilian government. The tender was present favoring Sigman as “author of the initiative”, with the commitment to acquire all the vaccines produc. The agreement was made with the multinational Novartis, which would have a three-year.
